옵션 체인은 다양한 행사가격과 만기일에 대한 HCW Biologics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 HCW Biologics에 대한 시장 심리를 평가합니다..

HCW Biologics (NASDAQ:HCWB) 주식, 옵션 체인

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

News

PepsiCo CEO Says Co Has Not Seen Direct Impact Of GLP-1 Drugs

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst David Amsellem downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowered the price target from $66 to $36. Amphastar Pharma shares closed at $33.39 on Monday. <a href="https://www.benzinga.com/quote/AMPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Peter Arment downgraded Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Outperform to Neutral but raised the price target from $20 to $26. Triumph Group shares closed at $25.10 on Monday. <a href="https://www.benzinga.com/quote/TTGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik downgraded the rating for Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and lowered the price target from $125 to $111. Ollie&#8217;s Bargain shares closed at $107.63 on Monday. <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and cut the price target from $20.5 to $15. Calumet shares closed at $18.34 on Monday. <a href="https://www.benzinga.com/quote/CLMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Trevor Allinson downgraded the rating for American Woodmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) from Outperform to Peer Perform. American Woodmark shares closed at $75.65 on Monday. <a href="https://www.benzinga.com/quote/AMWD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OLLI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png" alt="" class="wp-image-764859" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMPH

AMWD

CLMT

OLLI

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

<a href="https://www.ft.com/content/2ec45e79-9502-4ffd-82e8-888d9283c776" title="https://www.ft.com/content/2ec45e79-9502-4ffd-82e8-888d9283c776">https://www.ft.com/content/2ec45e79-9502-4ffd-82e8-888d9283c776</a>

Legal

Global

GOOG

GOOGL

INTC

NVDA

'China Targets Google, Nvidia And Intel As Trump Tariffs Bite' - Financial Times

WIIM

LVRO

Lavoro shares are trading lower after Canaccord Genuity cut its price target on the stock from $6.25 to $5.5.

MAIA

MAIA Biotechnology shares are trading higher after the company announced updated data from its THIO-101 Phase 2 clinical trial evaluating THIO.

China responds to the across-the-board 10% tariffs imposed by Donald Trump&#8216;s administration with targeted measures on a range of U.S. energy imports and restrictions on key minerals exports, officially reopening a new chapter in the trade war between the <a href="https://www.benzinga.com/news/econ-s">world&#8217;s two largest economies.</a>
&#8220;The unilateral increase in tariffs by the United States seriously violates the rules of the World Trade Organization,&#8221; the Ministry of Finance of the People&#8217;s Republic of China stated Tuesday. 
<h3 class="wp-block-heading">What Happened</h3>
As the U.S. implemented a 10% tariff on all Chinese imports, China responded on Feb. 4 with a series of countermeasures.
These included:
<ol>
<li>Raising tariffs by 10-15% on certain U.S. imports such as coal, liquified natural gas, crude oil, agricultural machinery and vehicles.</li>
<li>Imposing export restrictions on key minerals like tungsten, tellurium, bismuth, molybdenum, and indium, along with their related metallic compounds.</li>
<li>Adding two U.S. companies, PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), to its Unreliable Entity List in order to &#8220;safeguard national sovereignty, security and development interests.&#8221; According to China, these companies &#8220;violated the principles of normal market transactions, interrupted normal transactions with Chinese enterprises, and took discriminatory measures against Chinese enterprises.&#8221;&nbsp;</li>
<li>Initiating an antitrust investigation into Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).</li>
</ol>
According to an official statement, China&#8217;s retaliatory tariffs on U.S. goods will take effect on Feb. 10, while the export ban on critical minerals has already been enforced.
The&nbsp;Executive Order&nbsp;signed by Trump on Feb. 1 stated that if China were to retaliate by imposing additional tariffs on US goods, the 10% tariff rate might be raised further.&nbsp;
<h3 class="wp-block-heading">Why It Matters</h3>
Goldman Sachs economist Andrew Tilton indicates that China&#8217;s newly announced retaliatory tariffs cover a much narrower range of goods compared to the broad 10% U.S. tariff on Chinese imports. 
The combination of tariffs, export restrictions, entity list designations and antitrust investigations suggests a more strategic and coordinated policy response than during the 2018-19 trade war, according to the expert.
Goldman Sachs&#8217; estimates indicate that the U.S. accounts for a relatively small share of China&#8217;s imports in the targeted energy sectors. In 2024, China imported $4.5 billion worth of coal and LNG from the U.S., representing just 5% of its total imports for these products. For crude oil, U.S. exports to China totaled $9.4 billion, making up only 3% of China&#8217;s total crude imports.
Based on the investment bank&#8217;s calculations, the impact of China&#8217;s counter tariffs is &#8220;much-less than proportional,&#8221; as China is effectively imposing an additional 12% tariff on $14 billion in U.S. goods, compared to the U.S. implementing a 10% tariff on $525 billion worth of Chinese products.
Yet, &#8220;the future path of US-China trade conflicts remains highly uncertain, and reactions from the US to China's retaliation, the potential Trump-Xi phone call, and PBOC&#8217;s daily USDCNY fixing in the coming days are key events to watch,&#8221; Tilton says. 
<h3 class="wp-block-heading">Market Reactions </h3>
The Chinese yuan gained marginal ground against the U.S. dollar on Tuesday, up 0.2% by 8:15 a.m. in New York. 
China&#8217;s trade measures weighed on energy commodities, with futures on WTI and natural gas down 1.7% and 4%, respectively. Gold prices rose 0.3% to $2,830 per ounce, setting new all-time highs. 
Futures on major U.S. indices were mixed during Tuesday premarket trading, with contracts on the S&amp;P 500 up 0.3% while those on the Dow edging 0.1% lower. 
US-listed Chinese stocks rallied in the premarket. Shares of Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose 2%, PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) surged 2.1% and JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) rallied 2.6%. 
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) was 1.8% higher. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43450261/trump-trudeau-strike-border-security-deal-tariffs-on-canada-paused-for-at-least-30-days">Trump, Trudeau Strike Border Security Deal, Tariffs On Canada Paused For &#8216;At Least 30 Days &#8216;</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Government

Large Cap

Regulations

Specialty ETFs

Emerging Market ETFs

Commodities

Forex

Econ #s

Tech

ETFs

BABA

ILMN

Citigourp Global Markets 2% Protected Notes Linked To The Djia

China Strikes Retaliatory Measures Against US Following Trump's 10% Tariffs: It's 'Much-Less Than Proportional,' Analyst Says

Macro Economic Events

Economics

Redbook (YoY) 5.7% Vs 4.9% Prior

As Trump tariffs take another spin through Mexico and Canada, investors are left navigating an increasingly <a href="https://www.benzinga.com/topic/tariffs">complex trade landscape</a>. 
While the long-term economic impact remains "indeterminate for both the U.S. and others," Sam Rines, macro strategist at WisdomTree, sees this as a pivotal stress test for economies and supply chains that have hardened over the past six years.
<h2 class="wp-block-heading">Mexico &amp; Canada: The First To React To Trump Tariffs</h2>
In a <a href="https://www.benzinga.com/government/regulations/25/02/43440692/us-mexico-agrees-on-one-month-tariffs-pause-stocks-rebound-peso-rallies">swift diplomatic maneuver</a>, Mexico and the U.S. have reached what Rines calls "a détente of sorts." It may not be a full-fledged trade agreement, but it's enough of a political win for Trump to delay and reassess.
Canada has also<a href="https://www.benzinga.com/25/02/43450261/trump-trudeau-strike-border-security-deal-tariffs-on-canada-paused-for-at-least-30-days"> reached a temporary agreement</a> with the U.S., while the EU is bracing for its turn in the trade spotlight. Interestingly, "India (and others) are not being mentioned in the same context," a nod to Prime Minister Narendra Modi's past alignment with Donald Trump.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43432736/copper-stocks-on-shaky-ground-jpmorgan-analysts-say-tariffs-deepseek-cloud-outlook">Copper Stocks On Shaky Ground, JPMorgan Analysts Say: Tariffs, DeepSeek Cloud Outlook</a>
<h2 class="wp-block-heading">Dividend Payers Take Center Stage</h2>
So, who benefits from a protracted tariff skirmish? "The winners in a prolonged trade and tariff skirmish are U.S. domestically focused businesses," Rines notes, pointing to value stocks with limited exposure to trade volatility.
Dividend payers stand out as particularly "attractive," with Rines emphasizing their resilience over buyback-heavy firms. Those companies prioritizing stable income distribution are likely to emerge as the "biggest winners."
<h2 class="wp-block-heading">ETFs To Watch</h2>
For US investors looking to capitalize, ETFs such as the Vanguard Dividend Appreciation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIG#NYSE">VIG</a>), iShares Select Dividend ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>), the WisdomTree U.S. High Dividend Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHS#NYSE">DHS</a>) and the WisdomTree U.S. Quality Dividend Growth Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGRW#NASDAQ">DGRW</a>) could offer exposure to resilient, dividend-paying U.S. firms. 
Those betting on an America-first trade boom might look at Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) for companies committed to consistent payouts.
Rines leaves no doubt that this turbulence is far from over: "America First economic policies are seizing the attention of the markets… this is not going to abate in the near future and neither will the consequent volatility." Investors should buckle up, as the tariff rollercoaster shows no signs of slowing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43437906/constellation-brands-most-exposed-name-as-trump-tariffs-go-live-analysts-advise-adjusting-prices">Constellation Brands &#8216;Most Exposed Name&#8217; As Trump Tariffs Go Live: Analysts Advise Adjusting Prices</a></li>
</ul>
Photo: Chip Somodevilla/Shutterstock.com

Analyst Color

Broad U.S. Equity ETFs

Dividends

DGRW

iShares Dow Jones Select Dividend Index Fund

SCHD

Dividend Stocks Could Be 'Biggest Winners' As Trump's Trade Moves Shake Markets: WisdomTree Expert

UAVS

AgEagle Aerial Systems shares are trading higher after the company announced it completed a flight demonstration of its eBee VISION Intelligence Surveillance and Reconnaissance UAS platform at the French Army's 61st Artillery Regiment's event.

Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) will release its fourth-quarter financial results, after the <a href="https://www.benzinga.com/quote/CMG/earnings">closing bell, on Tuesday, Feb. 4, 2025.</a>
Analysts expect the Newport Beach, California-based company to report quarterly earnings at 25 cents per share, up from 21 cents per share in the year-ago period. Chipotle projects quarterly revenue of $2.85 billion, compared to $2.52 billion a year earlier, according to data from Benzinga Pro.
Chipotle outperformed competitors in terms of customer visits with year-over-year visit growth in each month of 2024, according to data from Placer.ai.
Chipotle shares gained 0.02% to close at $58.36 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/CMG/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Raymond James analyst Brian Vaccaro maintained an Outperform rating and cut the price target from $72 to $69 on Jan. 28, 2025. This analyst has an accuracy rate of 81%.</li>
<li>Citigroup analyst Jon Tower maintained a Buy rating and cut the price target from $70 to $69 on Jan. 27, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Wedbush analyst Nick Setyan reiterated an Outperform rating with a price target of $69 on Jan. 22, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Barclays analyst Jeffrey Bernstein maintained an Equal-Weight rating and raised the price target from $60 to $63 on Jan. 7, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Oppenheimer analyst Brian Bittner maintained an Outperform rating and raised the price target from $65 to $69 on Jan. 7, 2025. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying CMG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04042855/image-15-1024x508.png" alt="" class="wp-image-764368" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04042855/image-15-1024x508.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04042855/image-15-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04042855/image-15-768x381.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04042855/image-15.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Earnings

Price Target

Top Wall Street Forecasters Revamp Chipotle Mexican Grill Price Expectations Ahead Of Q4 Earnings

Key drone innovation forum for the French Army features eBee VISION flight demonstration

Events

AgEagle Aerial Systems Completed Flight Demonstration Of eBee VISION Intelligence Surveillance And Reconnaissance UAS Platform At French Army's 61st Artillery Regiment's Event

GCTK

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

<ul>
<li>Median overall survival (OS) from THIO treatment extends to 16.9 months</li>
<li>Newest data strengthens regulatory strategy</li>
</ul>
MAIA Biotechnology, Inc., (NYSE:<a href="https://www.benzinga.com/stock/MAIA#NYSE">MAIA</a>) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo&#xAE;) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population) in parts A and B of the trial. The analysis demonstrated a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population1. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.2

Biotech

General

MAIA Biotechnology Announce Efficacy Updates For Phase 2 THIO-101 Trial In Advanced Non-Small Cell Lung Cancer; Median Overall Survival From THIO Treatment Extends To 16.9 Months

Wells Fargo analyst Daniel Politzer maintains Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Equal-Weight and raises the price target from $262 to $285.

Wells Fargo Maintains Equal-Weight on Marriott Intl, Raises Price Target to $285

MNTS

Momentus shares are trading higher after the company announced its proposal to perform an in-space demonstration flight of Rendezvous and Proximity Operations was selected by the U.S. Air Force Research Labs AFWERX organization.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Michael Lavery upgraded the rating for Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) from Underweight to Neutral and maintained the price target of $58. Tyson Foods shares closed at $57.74 on Monday. <a href="https://www.benzinga.com/quote/TSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Eric Handler upgraded AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) from Sell to Neutral and lowered the price target from $4 to $3.25. AMC shares closed at $3.08 on Monday. <a href="https://www.benzinga.com/quote/AMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Sanjit Singh upgraded the rating for Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) from Underweight to Equal-Weight and raised the price target from $60 to $95. Palantir shares closed at $83.74 on Monday. <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Duane Pfennigwerth upgraded Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from In-Line to Outperform and announced a $330 price target. Marriott shares closed at $290.46 on Monday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Jake Civiello upgraded the rating for Princeton Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPRN#NASDAQ">BPRN</a>) from Neutral to Buy and announced a $35 price target. Princeton Bancorp shares closed at $31.50 on Monday. <a href="https://www.benzinga.com/quote/BPRN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085018/image-2-3-1024x557.png" alt="" class="wp-image-764844" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085018/image-2-3-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085018/image-2-3-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085018/image-2-3-768x417.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085018/image-2-3.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Upgrades

BPRN

PLTR

This Marriott International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Wells Fargo analyst Chris Carey maintains Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) with a Equal-Weight and raises the price target from $157 to $161.

Wells Fargo Maintains Equal-Weight on Clorox, Raises Price Target to $161

Cantor Fitzgerald analyst Brett Knoblauch maintains Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Overweight and lowers the price target from $11 to $10.

CIFR

Cantor Fitzgerald Maintains Overweight on Cipher Mining, Lowers Price Target to $10

Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>), a U.S. commercial space company offering satellite buses, technologies, transportation, and other in-space transportation services, today announced that the U.S. Air Force Research Labs AFWERX organization has selected a proposal from Momentus to perform an in-space demonstration flight of a new, low-cost suite of multispectral sensors for Rendezvous and Proximity Operations (RPO).
AFWERX is the innovation arm of the U.S. Air Force under the Air Force Research Laboratory (AFRL). AFWERX has been chartered to bring cutting-edge ingenuity from small businesses to address the most pressing challenges of the Air Force.
In 2024, Momentus submitted a proposal under the AFWERX Challenge and was recently formally notified that its proposal for a Phase II Small Business Innovation Research (SBIR) project to perform a multi-spectral RPO demonstration was selected after evaluation in a competitive process. Momentus expects to complete contract negotiations shortly. This selection underscores Momentus&#39; commitment to pioneering innovative solutions for national defense.
Under the SBIR project, Momentus plans to use a Rendezvous and Proximity Operations (RPO) system it has developed using internal R&amp;D funds and use an optical sensor, infrared sensor, and a Lidar sensor. (Lidar is a remote-sensing technology that uses laser beams to measure distances and movement in an environment.)
A flight demonstration in early 2026 is planned that will show the ability for low-cost RPO sensors to safely guide the approach and rendezvous of a space vehicle with a previously uncharacterized client object using machine vision algorithms and data fusion developed by Momentus. Reducing the cost while ensuring high operational safety for in-space rendezvous is a key enabling technology needed for the future of in-space refueling of satellites, manufacturing, assembly, servicing, and debris removal.
The rendezvous sensor demonstration for AFWERX will join other payloads, including from the Department of Defense and commercial customers, on a mission that Momentus has contracted with SpaceX to join a Transporter rideshare launch in early 2026.
For this mission, Momentus has additional capacity to support customers planning LEO deployment and hosted payload missions in early 2026. Government and commercial customers interested in utilizing the ability of the Vigoride vehicle to cost-effectively launch and deliver microsatellites up to 200 kg and cubesats, provide average power up to 1kW, and deploy or operate hosted payloads in orbits above 500 km and below the International Space Station are encouraged to contact Momentus while booking opportunities remain open at <a href="mailto:sales@momentusspace.com">sales@momentusspace.com</a>

Contracts

Momentus Announces Selection By US Air Force's AFWERX For In-Space Demonstration Of Multi-Spectral RPO Sensors; Contract Negotiations Ongoing; Flight Set For Early 2026 On SpaceX Launch

Management

OKTA

Okta To Reduce Workforce By ~180 Employees; Reaffirms Financial Guidance For Q4 And FY25; Expects To Recognize $11M In Restructuring Charges In Q4

HCW Biologics reports Q3 results

HCW Biologics jumps on license agreement for immunotherapeutic product candidate

HCW Biologics (HCWB) and WY Biotech, a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell t...

HCW Biologics licenses proprietary preclinical molecule to WY Biotech

HCW Biologics (HCWB) "announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000...

HCW Biologics prices $6.9M registered direct offering at $1.03 per share

HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement

HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. has entered a $6.9 million securities purchase agreement with an instituti...

HCW Biologics Expands with New Financial Agreements

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on HCW Biologics (HCWB – Research Report). The associated price target i...

HCW Biologics Secures Strategic Agreements and Funding to Propel Growth and Innovation

HCW Biologics (HCWB) reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff that it had failed to...

HCW Biologics receives notice on failing to regain compliance from Nasdaq

HCW Biologics (HCWB) announced that Hing Wong, PhD., Founder and CEO, will serve as a panelist on Panel Discussion II of the 2025 GenScript Biotech...

HCW Biologics CEO to address opportunities, challenges in biomanufacturing

HCW Biologics ( ($HCWB) ) has shared an announcement. On February 3, 2025, HCW Biologics announced that the FDA has cleared its Investigational New...

HCW Biologics Advances with FDA Clearance for Trial

HCWB

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

IPOs

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Health Care

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Comments

HCW Biologics

HCW Biologics (HCWB) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌